获取和使用糖尿病技术与治疗方面的差异:一项叙述性综述
本叙述性综述应用新唯物主义理论,从临床试验、糖尿病技术、免疫治疗和辅助数字技术四个领域审视糖尿病照护中的差异,聚焦基于种族、族裔和社会经济地位的边缘化。少数群体在临床试验中代表性不足可能限制数据的普适性;技术获取差异受种族、族裔、社会经济地位和保险覆盖等交叉因素影响;免疫治疗获取差异部分源于研究代表性不足;数字鸿沟是不平等使用辅助数字技术的关键障碍。解决这些差异需要综合多层面策略,包括政策改变、改善技术获取和包容性研究实践。
要点
- 少数群体在糖尿病干预临床试验中代表性不足可能限制数据普适性。
- 糖尿病技术获取差异受种族、族裔、社会经济地位和保险覆盖等交叉因素影响。
- 数字鸿沟是使用辅助数字技术的关键障碍,涉及智能手机、宽带和远程医疗的不平等获取。
核心结论
- 解决这些差异需要综合多层面策略,认识到结构性不平等的复杂性,包括政策改变、改善技术获取和包容性研究实践。
研究设计与样本
- 本叙述性综述应用新唯物主义理论,聚焦基于种族、族裔和社会经济地位的边缘化,从临床试验、糖尿病技术、免疫治疗和辅助数字技术四个领域审视糖尿病照护差异。
主要发现
- 少数群体在糖尿病干预临床试验中代表性不足可能限制所生成数据的普适性。
- 糖尿病技术(如持续葡萄糖监测和人工胰腺系统)获取差异似乎受种族、族裔、社会经济地位和保险覆盖等交叉因素影响。
- 免疫治疗(尤其1型糖尿病)获取差异可能部分源于少数群体在研究中的代表性不足。
- 糖尿病照护中的数字鸿沟是使用辅助数字技术的关键障碍,涉及智能手机、宽带和远程医疗的不平等获取。
关键数值与推荐
- 导致代表性不足的因素包括历史不信任、排除性标准和研究中缺乏文化能力。
- 解决差异的潜在方案包括修订试验方案、接触社区伙伴和改善招募策略,但检验这些方案的研究有限。
- 解决技术获取差异的方案可能涉及教育、改善获取和政策改革以应对健康的社会和结构决定因素。
- 解决免疫治疗获取差异的策略包括确保公平获取和对健康社会决定因素进行包容性数据收集。
- 弥合数字鸿沟需要改善基础设施、增加数字工具获取和有针对性的远程医疗干预以增强服务不足人群的照护。
临床怎么用
- 原文未据此给出推荐。
局限性
- 检验解决差异方案的研究有限。
- 尽管认识到这些差异,技术使用差距持续存在,因为决定这些差异的因果路径复杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This narrative review applies neo-materialist theory to examine disparities in diabetes care across four domains: clinical trials, diabetes technology, immunotherapies and adjuvant digital technologies. Although systemic marginalisation can occur in many forms (e.g. based on ability, language, sex, gender or age), this review focuses on marginalisation based on race, ethnicity and socioeconomic status, as these are the key areas supported by the current evidence base. Under-representation of minoritised groups in clinical trials of diabetes interventions may limit the generalisability of the data generated. Contributing factors to under-representation include historical mistrust, exclusionary criteria and lack of cultural competence in research. Potential solutions to these disparities include revising trial protocols, engaging community partners and improving recruitment strategies; however, studies examining these solutions are limited. Disparities in access to diabetes technologies, such as continuous glucose monitoring and artificial pancreas systems, appear to be influenced by intersectional factors including race, ethnicity, socioeconomic status and insurance coverage. Despite awareness of these disparities, gaps in technology use persist because the causal pathways that determine these disparities are complex. Solutions are likely to involve education, improved access and policy reforms to address social and structural determinants of health. Disparities in access to immunotherapies, particularly in type 1 diabetes, may stem in part from under-representation of minoritised groups in research. Strategies to address these disparities include ensuring equitable access and performing inclusive data collection on social determinants of health. The digital divide in diabetes care is a key barrier to adjuvant digital technology use, with unequal access to smartphones, broadband and telemedicine. Bridging this gap will require improved infrastructure, increased access to digital tools and targeted telemedicine interventions to enhance care in underserved populations. Addressing these disparities requires comprehensive multifaceted strategies that recognise the complexity of structural inequities, including policy changes, improved technology access and inclusive research practices.
引用
- Addala A, Amedari MI, Figg LE, et al. Disparities in access to and use of diabetes technologies and therapeutics: a narrative review. Diabetologia. 2025. PMID: 40696181. doi:10.1007/s00125-025-06494-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。